文献速递免疫规划

脂质体偶联pH敏感聚合物与树突状细胞靶向Toll样受体配体在肿瘤免疫治疗中激发强效佐剂效应

Potent adjuvant effect elicited for tumor immunotherapy by a liposome conjugated pH-sensitive polymer and dendritic cell-targeting Toll-like-receptor ligand.
PubMed 文献 · Vaccine · 2022-02-04

研究开发了一种新型合成佐剂,由偶联树突状细胞靶向Toll样受体配体和pH敏感聚合物的脂质体组成,用于增强交叉呈递。体外小鼠树突状细胞实验显示该脂质体被选择性摄取并增强树突状细胞功能;小鼠免疫显著增强抗原特异性细胞毒性;荷瘤小鼠接种封装肿瘤抗原的脂质体诱导完全肿瘤缓解,并增强针对其他肿瘤抗原的细胞毒性。

要点

  • 脂质体被小鼠树突状细胞选择性摄取,显著增强树突状细胞功能并激活免疫应答。
  • 荷瘤小鼠接种封装肿瘤抗原的脂质体诱导完全肿瘤缓解。
  • 接种显著增强细胞毒性,靶向疫苗抗原及其他肿瘤抗原。

核心结论

  • 脂质体是开发具有高潜力引发抗原特异性免疫应答的树突状细胞的理想佐剂,是有望用于新抗原疫苗接种癌症治疗的工具。

研究设计与样本

  • 体外研究使用小鼠树突状细胞;小鼠免疫实验;荷瘤小鼠疫苗接种实验。

主要发现

  • 体外研究中,脂质体被小鼠树突状细胞选择性摄取,显著增强树突状细胞功能并激活免疫应答,将封装抗原的表位呈递于主要组织相容性复合体I类分子。
  • 用封装肿瘤抗原的脂质体免疫小鼠,显著增强抗原特异性细胞毒性。
  • 荷瘤小鼠接种封装肿瘤抗原的脂质体,诱导完全肿瘤缓解。
  • 接种显著增强细胞毒性,不仅靶向疫苗抗原,还靶向肿瘤细胞的其他抗原。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The generation of DCs with augmented functions is a strategy for obtaining satisfactory clinical outcomes in tumor immunotherapy. We developed a novel synthetic adjuvant comprising a liposome conjugated with a DC-targeting Toll-like-receptor ligand and a pH-sensitive polymer for augmenting cross-presentation. In an in vitro study using mouse DCs, these liposomes were selectively incorporated into DCs, significantly enhanced DC function and activated immune responses to present an epitope of the incorporated antigen on the major histocompatibility complex class I molecules. Immunization of mice with liposomes encapsulating a tumor antigen significantly enhanced antigen-specific cytotoxicity. In tumor-bearing mice, vaccination with liposomes encapsulating a tumor antigen elicited complete tumor remission. Furthermore, vaccination significantly enhanced cytotoxicity, targeting not only the vaccinated antigen but also the other antigens of the tumor cell. These results indicate that liposomes are an ideal adjuvant to develop DCs with considerably high potential to elicit antigen-specific immune responses; they are a promising tool for cancer therapy with neoantigen vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Watanabe S, Yuba E, Akazawa T, et al. Potent adjuvant effect elicited for tumor immunotherapy by a liposome conjugated pH-sensitive polymer and dendritic cell-targeting Toll-like-receptor ligand. Vaccine. 2022. PMID: 35131134. doi:10.1016/j.vaccine.2022.01.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。